On the public citation graph
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice
0 signed · 95 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cncr.22989openalex-snapshot
Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989–2003
inferredcites →https://doi.org/10.1007/s00277-016-2602-5openalex-snapshot
Characteristics and outcome of patients with primary CNS lymphoma in a “real-life” setting compared to a clinical trial
inferredcites →https://doi.org/10.1016/0197-2456(96)00075-xopenalex-snapshot
A note on quantifying follow-up in studies of failure time
inferredcites →https://doi.org/10.1016/j.surneu.2006.05.055openalex-snapshot
Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan
inferredcites →https://doi.org/10.1016/s0140-6736(09)61416-1openalex-snapshot
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
inferredcites →https://doi.org/10.1016/s2352-3026(16)00036-3openalex-snapshot
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
inferredcites →https://doi.org/10.1016/s2352-3026(17)30174-6openalex-snapshot
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
inferredcites →https://doi.org/10.1080/10428190802311441openalex-snapshot
Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment
inferredcites →https://doi.org/10.1093/annonc/mdv076openalex-snapshot
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
inferredcites →https://doi.org/10.1093/neuonc/now155openalex-snapshot
Long-term survival in AIDS-related primary central nervous system lymphoma
inferredcites →https://doi.org/10.1186/s12885-016-2311-4openalex-snapshot
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)
inferredcites →https://doi.org/10.1200/jco.2000.18.17.3144openalex-snapshot
Treatment for Primary CNS Lymphoma: The Next Step
inferredcites →https://doi.org/10.1200/jco.2003.01.135openalex-snapshot
Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
inferredcites →https://doi.org/10.1200/jco.2003.09.139openalex-snapshot
Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
inferredcites →https://doi.org/10.1200/jco.2005.13.524openalex-snapshot
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
inferredcites →https://doi.org/10.1200/jco.2006.08.2941openalex-snapshot
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
inferredcites →https://doi.org/10.1200/jco.2012.46.9957openalex-snapshot
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)
inferredcites →https://doi.org/10.1200/jco.2013.50.4910openalex-snapshot
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome
inferredcites →https://doi.org/10.1200/jco.2015.64.8634openalex-snapshot
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227
inferredcites →https://doi.org/10.1212/wnl.0000000000004265openalex-snapshot
Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy
inferredcites →https://doi.org/10.3324/haematol.2012.076075openalex-snapshot
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4590911openalex-extracted
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit PCNSL Patients – The Multicenter MARTA Study
inferred← citeshttps://doi.org/10.1002/hem3.70412openalex-snapshot
Spatial and multi‐omic profiling reveals pericyte‐derived CCL19 as a key prognostic factor in CNS lymphoma
inferred← citeshttps://doi.org/10.1002/hem3.89openalex-snapshot
Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up
inferred← citeshttps://doi.org/10.1002/hon.3148openalex-snapshot
Management of primary and secondary CNS lymphoma
inferred← citeshttps://doi.org/10.1002/hon.70142openalex-snapshot
Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
inferred← citeshttps://doi.org/10.1002/ijc.70507openalex-snapshot
Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma
inferred← citeshttps://doi.org/10.1002/jha2.951openalex-snapshot
Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance
inferred← citeshttps://doi.org/10.1007/s00277-023-05140-6openalex-snapshot
Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry
inferred← citeshttps://doi.org/10.1007/s00432-024-05945-6openalex-snapshot
A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment
inferred← citeshttps://doi.org/10.1007/s00701-022-05170-5openalex-snapshot
Diagnosis, treatment, and outcome of primary CNS lymphoma—a single-center experience
inferred← citeshttps://doi.org/10.1007/s00761-025-01714-3openalex-snapshot
Stellenwert der Hochdosischemotherapie bei der Therapie primärer Lymphome des zentralen Nervensystems
inferred← citeshttps://doi.org/10.1007/s10238-023-01182-2openalex-snapshot
Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan
inferred← citeshttps://doi.org/10.1007/s10637-025-01548-1openalex-snapshot
Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1007/s11940-021-00668-2openalex-snapshot
Innovative Therapeutic Strategies for Primary CNS Lymphoma
inferred← citeshttps://doi.org/10.1007/s12185-025-04089-8openalex-snapshot
A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis
inferred← citeshttps://doi.org/10.1016/j.annonc.2023.11.010openalex-snapshot
Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
inferred← citeshttps://doi.org/10.1016/j.bneo.2025.100102openalex-snapshot
Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma
inferred← citeshttps://doi.org/10.1016/j.bneo.2026.100200openalex-snapshot
Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease
inferred← citeshttps://doi.org/10.1016/j.clml.2024.11.008openalex-snapshot
De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma
inferred← citeshttps://doi.org/10.1016/j.clml.2026.08.017openalex-snapshot
A Single-center Retrospective Study of MIAD ± R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes
inferred← citeshttps://doi.org/10.1016/j.clml.2026.10.005openalex-snapshot
A Real-World Experience with First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.104928openalex-snapshot
Real-world analysis of primary central nervous system diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.ejca.2025.116070openalex-snapshot
Large B-cell lymphoma: The LYSA pragmatic guidelines
inferred← citeshttps://doi.org/10.1016/j.prp.2020.153192openalex-snapshot
HIV prevalence in primary central nervous system lymphoma: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/s0140-6736(26)00917-7openalex-snapshot
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial
inferred← citeshttps://doi.org/10.1016/s0246-0378(26)47487-4openalex-snapshot
Lymphomes intracrâniens
inferred← citeshttps://doi.org/10.1016/s2352-3026(20)30366-5openalex-snapshot
MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
inferred← citeshttps://doi.org/10.1016/s2352-3026(24)00104-2openalex-snapshot
Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10
inferred← citeshttps://doi.org/10.1038/s41375-022-01582-5openalex-snapshot
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
inferred← citeshttps://doi.org/10.1038/s41408-025-01278-wopenalex-snapshot
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1038/s41409-025-02772-2openalex-snapshot
Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis
inferred← citeshttps://doi.org/10.1038/s41421-023-00559-7openalex-snapshot
Single-cell landscape of primary central nervous system diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1038/s41572-023-00439-0openalex-snapshot
Primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1053/j.seminhematol.2023.11.003openalex-snapshot
Evidence-based management of primary and secondary CNS lymphoma
inferred← citeshttps://doi.org/10.1080/10428194.2021.2024818openalex-snapshot
High-dose methotrexate dosing strategy in primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1080/10428194.2022.2064996openalex-snapshot
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma
inferred← citeshttps://doi.org/10.1080/16078454.2023.2243424openalex-snapshot
Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1097/cco.0000000000000975openalex-snapshot
First line treatments in primary central nervous system lymphomas in young patients
inferred← citeshttps://doi.org/10.1097/cco.0000000000001165openalex-snapshot
New treatment strategies for primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1097/icb.0000000000001255openalex-snapshot
PRIMARY CENTRAL NERVOUS SYSTEM AND VITREORETINAL LYMPHOMA MIMICKING VIRAL RETINITIS IN A YOUNG PATIENT
inferred← citeshttps://doi.org/10.1111/bjh.17799openalex-snapshot
Advances in treatment of elderly primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1111/bjh.18539openalex-snapshot
Management of secondary central nervous system lymphoma
inferred← citeshttps://doi.org/10.1111/bjh.18687openalex-snapshot
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine ( R‐MIV ) in patients with primary CNS lymphoma including recent COVID ‐19 pandemic experience
inferred← citeshttps://doi.org/10.1111/ejh.13639openalex-snapshot
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine
inferred← citeshttps://doi.org/10.1111/ejh.14159openalex-snapshot
Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients
inferred← citeshttps://doi.org/10.1159/000537995openalex-snapshot
Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma
inferred← citeshttps://doi.org/10.1182/blood.2023020168openalex-snapshot
How I treat secondary CNS involvement by aggressive lymphomas
inferred← citeshttps://doi.org/10.1182/bloodadvances.2021004779openalex-snapshot
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
inferred← citeshttps://doi.org/10.1182/bloodadvances.2024014588openalex-snapshot
Time to revisit reduced-dose radiotherapy for PCNSL?
inferred← citeshttps://doi.org/10.1182/hematology.2022000331openalex-snapshot
CNS prophylaxis in aggressive B-cell lymphoma
inferred← citeshttps://doi.org/10.1186/s12885-022-09723-wopenalex-snapshot
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma
inferred← citeshttps://doi.org/10.1186/s12885-023-11193-7openalex-snapshot
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial
inferred← citeshttps://doi.org/10.1186/s13045-024-01606-wopenalex-snapshot
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
inferred← citeshttps://doi.org/10.1186/s13045-025-01700-7openalex-snapshot
PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma
inferred← citeshttps://doi.org/10.1200/op.23.00294openalex-snapshot
Diagnostic, Pathologic, and Therapeutic Considerations for Primary CNS Lymphoma
inferred← citeshttps://doi.org/10.17116/onkolog20221106149openalex-snapshot
Modern aspects of the diagnosis and treatment of primary central nervous system lymphomas
inferred← citeshttps://doi.org/10.17116/onkolog20231206182openalex-snapshot
Primary lymphomas of the central nervous system
inferred← citeshttps://doi.org/10.17650/1818-8346-2021-16-2-10-20openalex-snapshot
Treatment of primary central nervous system lymphomas
inferred← citeshttps://doi.org/10.21037/aol-20-30openalex-snapshot
Treatment of elderly patients with primary CNS lymphoma
inferred← citeshttps://doi.org/10.21037/aol-21-20openalex-snapshot
Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1621534/v1openalex-snapshot
Specific KIR-HLA genotypes predict outcomes of refractory or recurrent primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2135092/v1openalex-snapshot
Specific KIR-HLA genotypes predict the outcomes of refractory or recurrent primary central nervous system lymphoma
inferred← citeshttps://doi.org/10.3324/haematol.2022.281457openalex-snapshot
Prevention and management of secondary central nervous system lymphoma
inferred← citeshttps://doi.org/10.3324/haematol.2022.282014openalex-snapshot
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1579483openalex-snapshot
Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study
inferred← citeshttps://doi.org/10.3389/fonc.2022.824632openalex-snapshot
PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
inferred← citeshttps://doi.org/10.3390/cancers13174268openalex-snapshot
Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
inferred← citeshttps://doi.org/10.3390/cancers15020526openalex-snapshot
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review
inferred← citeshttps://doi.org/10.3390/curroncol33090557openalex-snapshot
Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study
inferred← citeshttps://doi.org/10.3390/hematolrep17060055openalex-snapshot
Outcomes for Primary Central Nervous System Lymphoma from a Single Institution
inferred← citeshttps://doi.org/10.3390/ijms262110521openalex-snapshot
Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era
inferred← citeshttps://doi.org/10.3390/jpm13071182openalex-snapshot
Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy
inferred← citeshttps://doi.org/10.58931/cht.2025.4274openalex-snapshot
Management of Newly Diagnosed Primary Central Nervous System Lymphoma
inferred← citeshttps://doi.org/10.7759/cureus.14394openalex-snapshot
Primary Central Nervous System T-cell Lymphoma Associated With Hepatitis B and D Virus Coinfection
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.